CRISPR and Gene Editing in Treating Vascular Disease

Cardiovascular Gene Therapy: Gene Editing for Heart Disease

Cardiovascular disease remains one of the top causes of death globally, causing about 32 percent of deaths worldwide, according to the World Health Organization (WHO). Gene editing, CRISPR (short for “clustered regularly interspaced short palindromic repeats”) in particular, offers great promise for effective treatment, though research is still in the early stages. While CRISPR was initially approved for the treatment of sickle cell disease, there are currently CRISPR vascular therapy trials that address several types of cardiovascular disease.

CRISPR Success Stories and Vascular Health Breakthroughs

The first major success story with CRISPR began in 2019, when the first patient received this gene therapy for sickle cell disease. In a matter of months, the patient went from frequent hospitalization to a significant improvement of her condition. The improvement has proven to be long-lasting, and today she lives a full, active life, free from debilitating pain. CRISPR is also in clinical trials to treat beta-thalassemia, a blood disorder that inhibits the body’s production of hemoglobin, and the results are very promising. In fact, the success in treating beta-thalassemia is raising hopes about treating other genetic blood disorders.

What is CRISPR and How Does it Work?

You may have heard some news about CRISPR, yet still have no idea of the mechanism behind it. CRISPR is an immune system used by microbes to protect against viruses. Researchers are learning how to use this in gene editing, developing therapies that treat various illnesses. Using CRISPR, scientists can target specific genes, in order to remove, repair, or replace them.

CRISPR in Vascular Disease Treatment

Modern treatments for cardiovascular disease have come a long way, with medications, minimally invasive procedures, and advanced surgical techniques helping millions of patients live longer, healthier lives. At the same time, continued innovation is vital to further improving outcomes and addressing the global burden of cardiovascular disease. As researchers explore new approaches, the emergence of CRISPR gene-editing strategies represents an exciting and promising frontier. So far, CRISPR is being used to treat hereditary mutations that cause heart disease, which is beneficial but not broadly applicable, because these mutations are not common. However, strides are being made, and the first bespoke CRISPR treatment was recently administered to an infant. As we gain more knowledge and insight into CRISPR, more uses will be developed to treat more illnesses. Currently, clinical trials are being conducted to address abnormally high cholesterol, a type of heart failure related to amyloid deposits, and a genetic condition that causes abnormally high cholesterol.  So far, the results are encouraging.

Benefits, Challenges, and Lessons Learned from CRISPR Vascular Therapy Trials

The benefits of CRISPR for cardiovascular treatments, as demonstrated in clinical trials, could be substantial. In one trial of 15 participants with lipid disorders, a single infusion of a CRISPR therapy significantly reduced both LDL cholesterol and triglycerides. This could be huge for people with high cholesterol, and could even eliminate the need for weekly or monthly medication, fixing the problem all at once. Of the 15 people, three had minor reactions related to the infusion, like back pain or nausea. Another participant who had elevated liver enzymes at the start of the trial experienced a temporary further elevation, lasting only a few days. Given this information, it seems the benefits of gene editing using CRISPR far outweigh the drawbacks.

Future Outlook: Advances in Gene Editing for Cardiology

As our understanding of this particular type of gene editing progresses, caution must be taken to ensure that we wisely use this new method of manipulating genetics. Inappropriate usage of gene editing, for creating “designer babies”, for instance, is obviously questionable. There are a number of ongoing clinical trials, though, that show great promise in treating both common and uncommon illnesses.

If You Have Genetic Markers for Arterial Disease or Heart Disease, Contact ReVaMP

At ReVaMP Heart and Vascular Institute, our dedicated physicians specialize in treating a wide range of cardiovascular conditions, with leading-edge technologies, innovative procedures, and a patient-centered approach. Since 2021, we have been serving patients within the Philadelphia and Southern NJ regions, treating a wide range of cardiovascular conditions, with a focus on preventative and minimally invasive care. We provide coronary, structural, peripheral arterial, and venous interventions that enhance our patients’ quality of life and renew their health and well-being. Using a tailored approach, our expert physicians take the time to understand each patient to craft a treatment plan that meets the patient’s unique needs. For more information about our modern, patient-focused cardiovascular care, contact us through our website.